ライフサイエンスコーパス: bullous

1 f fever, widespread infiltrated plaques with bullous appearance, and variable involvement of the arms

2 Pemphigus vulgaris is a life threatening bullous autoimmune disease of the skin mediated by autoa

3 Bullous congenital ichthyosiform erythroderma (BCIE) is

4 antar epidermis, in comparison with cases of bullous congenital ichthyosiform erythroderma also due t

5 ted a mouse model for the human skin disease bullous congenital ichthyosiform erythroderma by gene ta

6 hthyosis is a distinct phenotypic variant of bullous congenital ichthyosiform erythroderma that has r

7 sults in a phenotype distinct from classical bullous congenital ichthyosiform erythroderma.

8 Mean subfoveal choroidal thickness in the bullous CSC group (463.1+/-83.1 mum) was not different c

9 ified in a greater proportion of eyes in the bullous CSC group (both P < 0.001).

10 The bullous CSC group demonstrated a greater number of pigme

11 More eyes in the bullous CSC group demonstrated hyperreflectivity around

12 Mean age of the bullous CSC group was 53.8 years.

13 In autoimmune bullous dermatoses (AIBD), autoantibodies induce blister

14 d aberrant cytokine expression in autoimmune bullous dermatoses (AIBDs), cytokine-targeting therapies

15 Adequate treatment of bullous dermatoses may be associated with a decrease in

16 om the sera of some patients with linear IgA bullous dermatosis (LABD) recognize a 97 kDa antigen (LA

17 CBDC and its adult counter-part, linear IgA bullous dermatosis (LABD), are characterized by linear d

18 Bullous pemphigoid (BP) is a bullous dermatosis associated with autoantibodies direct

19 ent protein that is the target of linear IgA bullous dermatosis autoantibodies.

20 he autoimmune blistering disorder linear IgA bullous dermatosis specifically recognized bands of 120

21 f autoantibodies in patients with linear IgA bullous dermatosis.

22 Transient bullous dermolysis of the newborn (TBDN) is a blistering

23 area (0.561 vs. 0.499, p = 0.040), and less bullous disease (1.7 vs. 2.6, p = 0.011) compared with r

24 ship between percentage change in FEV(1) and bullous disease and inverse relationships between percen

25 r age of these patients with lung cancer and bullous disease as compared with those reported in the l

26 lysis bullosa acquisita (EBA), an autoimmune bullous disease caused by autoantibodies to type VII col

27 ctional epidermolysis bullosa is a heritable bullous disease caused by mutations found primarily in t

28 idermolysis bullosa acquisita, an autoimmune bullous disease characterized by autoantibodies against

29 (CT) of the chest in screening patients with bullous disease for lung cancer is discussed.

30 Pemphigus vulgaris (PV) is an autoimmune bullous disease in which autoantibodies against proteins

31 Chronic bullous disease of childhood (CBDC) is an autoimmune bli

32 We present six cases in which bullous disease of the lung and lung cancer coexisted, a

33 in the literature of an association between bullous disease of the lung and lung cancer; however, we

34 lysis bullosa acquisita (EBA) is an acquired bullous disease of the skin characterized by IgG autoant

35 Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin characterized by subepiderma

36 was used to build a 45-item pilot Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire, d

37 Experts in bullous disease refined the pilot ABQOL before factor an

38 Disease Area Index (R = 0.42) and Autoimmune Bullous Disease Skin Disorder Intensity Score (R = 0.48)

39 the literature with lung cancer but without bullous disease suggests that the association between th

40 ic inflammation, peribronchial fibrosis, and bullous disease were assessed semiquantitatively.

41 idermolysis bullosa (DEB), a genetic mechano-bullous disease.

42 the latter being the most common autoimmune bullous disease.

43 t of IVIG in autoantibody-mediated cutaneous bullous diseases is to accelerate the degradation of pat

44 In conclusion, there are now three bullous diseases, bullous pemphigoid, herpes gestationis

45 t for >30 disorders, including numerous skin bullous diseases, myopathies, neuropathies, and even pro

46 atosus, psoriasis, lichen planus, autoimmune bullous diseases, systemic sclerosis, morphea, hidradeni

47 ingle national referral center on autoimmune bullous diseases.

48 a referral university center for autoimmune bullous diseases.

49 olysis bullosa (DEB) is an inherited mechano-bullous disorder caused by mutations in the type VII col

50 ermolysis bullosa simplex (EBS) is a mechano-bullous disorder characterized by intraepidermal blister

51 olysis bullosa (DEB) is an inherited mechano-bullous disorder of skin caused by mutations in the type

52 n underlying vulvar dermatosis or autoimmune bullous disorder.

53 llosa (DEB) is a family of inherited mechano-bullous disorders caused by mutations in the human type

54 The pemphigus family of autoimmune bullous disorders is characterized by autoantibody bindi

55 idermolysis bullosa is a group of hereditary bullous disorders resulting from defects in several hemi

56 llosa (DEB) is a family of inherited mechano-bullous disorders that are caused by mutations in the ty

57 om a tertiary referral center for autoimmune bullous disorders.

58 ilation defects were shown in a patient with bullous emphysema, and ventilation-perfusion mismatches

59 Six episodes of reticular bullous epithelial corneal edema were identified in 5 ey

60 netarsudil produced a particular pattern of bullous epithelial corneal edema.

61 All patients demonstrated improvement in bullous epithelial edema after netarsudil discontinuatio

62 In all cases, the reticular bullous epithelial edema improved or resolved after disc

63 history of a particular pattern of reticular bullous epithelial edema in a series of patients treated

64 cases, visual acuity worsened with onset of bullous epithelial edema, and in all cases, visual acuit

65 A disease-revealing massive bullous eruption was noted in 9 patients (27.2%).

66 disease characterized by severe subepidermal bullous eruptions and renal insufficiency with IgG autoa

67 rane (eg, the pemphigoid group of disorders [bullous, gestational, and mucous membrane]) or impaired

68 helial tears were seen in 95% of eyes in the bullous group and none of the eyes in the nonbullous CSC

69 Individuals with this variant present with bullous ichthyosis in early childhood and hyperkeratotic

70 In the blistering diseases bullous impetigo and staphylococcal scalded-skin syndrom

71 Bullous impetigo due to Staphylococcus aureus is one of

72 In bullous impetigo, Staphylococcus aureus spreads under th

73 or Fuchs endothelial dystrophy (260 eyes) or bullous keratopathy (15 eyes).

74 5 DMEK cases were performed for pseudophakic bullous keratopathy (2 cases, 1 in each cohort), and the

75 Clinical outcomes of 23 DMEK procedures for bullous keratopathy (52%), failed previous transplant (3

76 PK) for Fuchs endothelial dystrophy (FED) or bullous keratopathy (BK) in Asian eyes.

77 dystrophy (FECD) subgroup, and 27.4% of the bullous keratopathy (BK) subgroup did not show visual im

78 dothelial corneal dystrophy (FECD; 85.3%) or bullous keratopathy (BK; 10.5%).

79 dothelial corneal dystrophy (FECD; n = 314), bullous keratopathy (BK; n = 31), and failed previous en

80 mpared with normal controls and pseudophakic bullous keratopathy (iatrogenic CE cell loss) specimens.

81 s endothelial corneal dystrophy (n = 28) and bullous keratopathy (n = 11).

82 SAEK graft failure (n = 3), and pseudophakic bullous keratopathy (n = 2).

83 gery (n = 127; 90%) followed by pseudophakic bullous keratopathy (n = 4; 4%) and regrafts (n = 9; 6.4

84 a), pseudophakic bullous keratopathy/aphakic bullous keratopathy (North America), and keratitis (Asia

85 mes than penetrating grafts for pseudophakic bullous keratopathy (P <0.001).

86 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy (PBK) at a single institution.

87 FED and pseudophakic bullous keratopathy (PBK) corneal buttons were removed d

88 ched normal autopsy corneas and pseudophakic bullous keratopathy (PBK) corneas.

89 elial dystrophy and 9 eyes with pseudophakic bullous keratopathy (PBK) that underwent DSAEK, and 17 e

90 hs endothelial dystrophy (FED), pseudophakic bullous keratopathy (PBK), infection and other indicatio

91 hs endothelial dystrophy (FED), pseudophakic bullous keratopathy (PBK), or keratoconus who had underg

92 ly a Descemet membrane disorder), but not in bullous keratopathy (primarily an endothelial depletion)

93 was strongest in patients with pseudophakic bullous keratopathy (r = -0.62 [P = .01]).

94 dothelial corneal dystrophy [FECD]: n = 111; bullous keratopathy [BK]: n = 24; and failed graft: n =

95 captured by tear lipocalin from corneas with bullous keratopathy and dry eye.

96 erformed on eight cases each of pseudophakic bullous keratopathy and healthy corneas.

97 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy at a single tertiary center.

98 primary surgical indication was pseudophakic bullous keratopathy at a single tertiary center.

99 he hypothesis that epithelial alterations in bullous keratopathy compromise the surface of the cornea

100 DNA damage was not detected in pseudophakic bullous keratopathy corneas, whereas it colocalized with

101 In contrast, none of the bullous keratopathy eyes showed any improvement througho

102 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy from January 2006 through December 2

103 uchs' endothelial dystrophy and pseudophakic bullous keratopathy in patients without other vision-lim

104 MEK surgery in the treatment of pseudophakic bullous keratopathy in the presence of sf-IOL and if-IOL

105 Pseudophakic bullous keratopathy manifests an abnormal corneal ocular

106 ll and superficial cell layers were lower in bullous keratopathy specimens (1.6 vs. 2.0; P < 0.0001)

107 ers evident in sections was increased in the bullous keratopathy specimens compared with controls (0.

108 orated with antibodies to MUC16 was lower in bullous keratopathy specimens than in controls (0.5 vs.

109 Fuchs endothelial dystrophy and pseudophakic bullous keratopathy undergoing DSAEK surgery were includ

110 monstrated in a pre-clinical rabbit model of bullous keratopathy using a tissue-engineered endothelia

111 EK failure in pseudophakic bullous keratopathy was associated with center experienc

112 The reduction of layers expressing MUC1 in bullous keratopathy was not statistically significant.

113 rformed for Fuchs' dystrophy or pseudophakic bullous keratopathy was poorer than survival of penetrat

114 Fuchs' endothelial dystrophy or pseudophakic bullous keratopathy were randomized to DMEK or UT-DSAEK

115 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy who were considered good candidates

116 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy who were good candidates for DMEK or

117 o be effective in symptomatic improvement of bullous keratopathy, and infectious keratitis but furthe

118 ycans from human corneas with chronic edema, bullous keratopathy, and keratoconus and from normal cor

119 the most common indication for PTK is still bullous keratopathy, as PTK can be successfully used whi

120 Fuchs endothelial dystrophy and pseudophakic bullous keratopathy, EK achieved better average best-cor

121 In our study of eyes with bullous keratopathy, endothelial keratoplasty under a pr

122 ssociated with Fuchs' endothelial dystrophy, bullous keratopathy, iridocorneal endothelial syndrome o

123 For optical grafts, pseudophakic bullous keratopathy, postinfectious corneal scarring and

124 In eyes with pseudophakic bullous keratopathy, the EndoGlide group had a superior

125 s associated with them, such as pseudophakic bullous keratopathy, uveitis-glaucoma-hyphema syndrome,

126 p is strongest in patients with pseudophakic bullous keratopathy.

127 from Fuchs endothelial dystrophy and 5 with bullous keratopathy.

128 Fuchs endothelial dystrophy or pseudophakic bullous keratopathy.

129 y was also assessed within a rabbit model of bullous keratopathy.

130 of cellular adhesion molecules is altered in bullous keratopathy.

131 tes the dominant features of contemporaneous bullous keratopathy.

132 lay a significant role in the progression of bullous keratopathy.

133 nderwent DSAEK procedure due to pseudophakic bullous keratopathy.

134 tial relief to patients who develop it after bullous keratopathy.

135 ter graft survival in eyes with pseudophakic bullous keratopathy.

136 formed for Fuchs' dystrophy and pseudophakic bullous keratopathy.

137 secondary corneal edema due to pseudophakic bullous keratopathy.

138 st, Africa, and South America), pseudophakic bullous keratopathy/aphakic bullous keratopathy (North A

139 For bullous keratoplasty and/or corneal edema, 8.6% and 22%

140 f anti-type VII collagen IgG increased after bullous lesions appeared.

141 re genetic condition typified by superficial bullous lesions following incident frictional trauma to

142 re genetic condition typified by superficial bullous lesions that result from frictional trauma to th

143 Histology showed bullous lesions with an epidermal-dermal separation.

144 levels observed before the inception of the bullous lesions.

145 salt-split indirect immunofluorescence, and bullous pemphigoid (BP) 230 and BP180-NC16A ELISAs.

146 Affiliated Hospitals with a new diagnosis of bullous pemphigoid (BP) between May 1, 1997 and Septembe

147 Bullous pemphigoid (BP) has been previously described to

148 Although predisposing factors for bullous pemphigoid (BP) have been recently established,

149 Bullous pemphigoid (BP) is a bullous dermatosis associat

150 Bullous pemphigoid (BP) is a subepidermal blistering dis

151 Bullous pemphigoid (BP) is a subepidermal blistering dis

152 Bullous pemphigoid (BP) is a subepidermal blistering dis

153 Bullous pemphigoid (BP) is an autoantibody-mediated blis

154 Bullous pemphigoid (BP) is an autoimmune bullous disease

155 Bullous pemphigoid (BP) is an autoimmune disease associa

156 Bullous pemphigoid (BP) is an autoimmune disease charact

157 Bullous pemphigoid (BP) is an autoimmune skin disease ch

158 Bullous pemphigoid (BP) is an autoimmune skin disease ch

159 Bullous pemphigoid (BP) is an autoimmune skin disease ch

160 Bullous pemphigoid (BP) is an autoimmune skin-blistering

161 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

162 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

163 Bullous pemphigoid (BP) is an autoimmune subepidermal bl

164 Bullous pemphigoid (BP) is an inflammatory subepidermal

165 Bullous pemphigoid (BP) is an inflammatory subepidermal

166 Bullous pemphigoid (BP) is by far the most frequent auto

167 Bullous pemphigoid (BP) is characterized by the depositi

168 tibodies from the sera of some patients with bullous pemphigoid (BP) react with a 180 kDa protein ter

169 Bullous pemphigoid (BP), a common autoimmune blistering

170 ation has long been a histologic hallmark of bullous pemphigoid (BP), a subepidermal autoimmune blist

171 ermal separation in an experimental model of bullous pemphigoid (BP), an autoimmune disease.

172 targeted by autoantibodies in patients with bullous pemphigoid (BP), and absent in patients with one

173 sera from patients with pemphigus vulgaris, bullous pemphigoid (BP), and chronic atopic and chronic

174 tients with a blistering skin disease called bullous pemphigoid (BP), is a transmembrane component of

175 rom patients with MMP, 1 of 50 patients with bullous pemphigoid (BP), none of 7 with pemphigus, and 3

176 e used IgG passive transfer murine models of bullous pemphigoid (BP), pemphigus foliaceus (PF), and p

177 The outcome of bullous pemphigoid (BP), the most frequent autoimmune sk

178 eurological disorders may be associated with bullous pemphigoid (BP).

179 reported sequence of the 180 kDa antigen in bullous pemphigoid (BPAg2).

180 systemic lupus erythematosus (BSLE) (n = 3), bullous pemphigoid (n = 16), pemphigus (n = 11), and nor

181 Pemphigus vulgaris (n=40, USA and Japan), bullous pemphigoid (n=40, USA), and healthy donors (n=55

182 nhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903).

183 p randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or mor

184 ibodies directed against the NC16A domain of bullous pemphigoid 180 (collagen XVII), a transmembrane

185 s that bind to this immunodominant region of bullous pemphigoid 180 are capable of inducing a skin di

186 d patients, all of whom had circulating anti-bullous pemphigoid 180 autoantibodies, showed a specific

187 ned autoantibody-reactive site recognized by bullous pemphigoid and herpes gestationis sera) and the

188 th two other autoimmune blistering diseases, bullous pemphigoid and herpes gestationis.

189 ednisolone for short-term blister control in bullous pemphigoid and significantly safer in the long-t

190 e dermal-epidermal-junction is a hallmark of bullous pemphigoid and was shown to be important for pat

191 These mice represent a bullous pemphigoid animal model featuring pruritus in im

192 esmosomal transmembrane protein, the 180 kDa bullous pemphigoid antigen (BP180), also known as type X

193 n utilizing primers specific for the 230 kDa bullous pemphigoid antigen (BPAG1), the 180 kDa bullous

194 The 180-kDa bullous pemphigoid antigen (BPAG2) is a candidate gene/p

195 lous pemphigoid antigen (BPAG1), the 180 kDa bullous pemphigoid antigen (BPAG2), the alpha6 and beta4

196 mma, activated the skin-specific promoter of bullous pemphigoid antigen 1 (BPAG-1).

197 Bullous pemphigoid antigen 1 (BPAG1) is a member of the

198 Bullous pemphigoid antigen 1 (BPAG1) is a member of the

199 They contain mutations in the gene encoding Bullous Pemphigoid Antigen 1 (BPAG1), or dystonin.

200 Bullous pemphigoid antigen 1 (BPAG1-e, also known as BP2

201 and is identical to the neuronal isoform of bullous pemphigoid antigen 1 (BPAG1-n).

202 Other plakins, such as bullous pemphigoid antigen 1 and microtubule and actin c

203 Disruption of the BPAG1 (bullous pemphigoid antigen 1) gene results in progressiv

204 proteins, to which envoplakin, desmoplakin, bullous pemphigoid antigen 1, and plectin belong.

205 led-coil domain of the epithelial isoform of bullous pemphigoid antigen 1, BPAG1-e (also known as BP2

206 gnized desmoplakin and plectin, and, weakly, bullous pemphigoid antigen 1.

207 Autoreactive T cells to an epitope of bullous pemphigoid antigen 180 kilodaltons were identifi

208 he beta4 integrin-associated plakin protein, bullous pemphigoid antigen 1e (BPAG1e) functions as a sc

209 integrin or knockdown of the plakin protein Bullous Pemphigoid Antigen 1e (BPAG1e).

210 Bullous pemphigoid antigen 2 (BPAG2) is targeted by auto

211 Skin grafts from mice expressing human bullous pemphigoid antigen 2 (hBPAG2) in epidermal basem

212 5 (p < 0.05), and in skin from patients with bullous pemphigoid antigen 2 mutations (n = 3) the count

213 roteins such as the integrin alpha6beta4 and bullous pemphigoid antigen 2 within the hemidesmosomes a

214 D97 is a component of the shed ectodomain of bullous pemphigoid antigen 2.

215 s reduced dynamics, and fails to recruit its bullous pemphigoid antigen binding partners.

216 The bullous pemphigoid antigen BPAG1 is required for keratin

217 ression of zinc finger protein 185 (ZNF185), bullous pemphigoid antigen gene (BPAG1), and prostate se

218 and attest to the importance of the 180-kDa bullous pemphigoid antigen in the attachment of the epid

219 A second bullous pemphigoid antigen of 180 kDa (BP180/BPAG2) is a

220 roteins and include desmoplakin, the 230 kDa bullous pemphigoid antigen, and envoplakin.

221 protein interacting with Nck (SPIN90/WISH), bullous pemphigoid antigen-1, and calcium channel beta2.

222 s of BMZ proteins: one enriched with the two bullous pemphigoid antigens (BP230, BP180) and one enric

223 he alpha6beta4 integrin, plectin, and BPAGs (bullous pemphigoid antigens).

224 Pemphigus and bullous pemphigoid are autoantibody-mediated blistering

225 Pemphigus and bullous pemphigoid are distinct autoimmune blistering di

226 has recently demonstrated that reactivity of bullous pemphigoid autoantibodies to the BP180 ectodomai

227 tandard techniques for detecting circulating bullous pemphigoid autoantibodies, including other enzym

228 h the 180 and 230 kDa proteins recognized by bullous pemphigoid autoantibodies, LABD97 has been thoug

229 t of the hemidesmosome plaque is the 230-kDa bullous pemphigoid autoantigen (BP230/BPAG1), which conn

230 ns regarding an experimental murine model of bullous pemphigoid by showing that the plasminogen/plasm

231 th BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 3

232 tream from the MCW-1 domain, the predominant bullous pemphigoid epitope.

233 In the literature, patients with bullous pemphigoid have been reported to have itch witho

234 Bullous pemphigoid is a blistering skin disease characte

235 Bullous pemphigoid is a blistering skin disorder with in

236 ostic assays and expertise and classified as bullous pemphigoid or epidermolysis bullosa acquisita.

237 stemic lupus erythematosus patients (n = 3), bullous pemphigoid patients (n = 15), and normal humans

238 T cells from eight of 12 bullous pemphigoid patients, all of whom had circulating

239 e examined the autoimmune T cell response in bullous pemphigoid patients.

240 sease-specific autoantibodies in the sera of bullous pemphigoid patients.

241 reas the predominant epitope identified with bullous pemphigoid sera is located in the noncollagenous

242 Of 50 randomly selected bullous pemphigoid sera tested, 47 (94%) were positive i

243 Interestingly, all three of the bullous pemphigoid sera that were negative in this assay

244 A potential role of Staphylococcus aureus in bullous pemphigoid was explored by examining the coloniz

245 (median [range] age, 75 [55-85] years) with bullous pemphigoid were included in the trial, of whom 5

246 .2% female; specifically, 6951 patients with bullous pemphigoid, 1669 patients with pemphigus, and 79

247 nic target of autoantibodies associated with bullous pemphigoid, a blistering skin disease.

248 mice would also be resistant to experimental bullous pemphigoid, a disease with a pathogenesis though

249 , pemphigus foliaceous, pemphigus, vulgaris, bullous pemphigoid, and benign chronic pemphigus, howeve

250 lupus erythematosus, angioedema, pemphigus, bullous pemphigoid, and HS.

251 heir first year of life, with uncontrollable bullous pemphigoid, colitis, and proteinuria.

252 d diagnosis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, muc

253 usion, there are now three bullous diseases, bullous pemphigoid, herpes gestationis, and cicatricial

254 ded, that is, chronic spontaneous urticaria, bullous pemphigoid, IgA (Henoch-Schonlein purpura) and I

255 l patients with immunopathologic findings of bullous pemphigoid, itch, and no blisters.

256 Sera from patients with bullous pemphigoid, pemphigus vulgaris, and cicatricial

257 inducing a skin disease that closely mimics bullous pemphigoid, supporting the hypothesis that epito

258 icture may be indistinguishable from that of bullous pemphigoid, the latter being the most common aut

259 sults with a complement-targeting therapy in bullous pemphigoid, to our knowledge, and supports furth

260 mmon in elderly patients, including scabies, bullous pemphigoid, transient acantholytic dermatosis, a

261 Earlier preliminary studies in humans with bullous pemphigoid, which is also associated with excess

262 The most common of these diseases is bullous pemphigoid, which mainly affects older people an

263 n that contains all four of the well-defined bullous pemphigoid-associated antigenic sites.

264 In the inflammatory (bullous pemphigoid-like) EBA variant, autoantibody bindi

265 ut blisters had immunopathologic findings of bullous pemphigoid.

266 hout skin lesions can be the only symptom of bullous pemphigoid.

267 en of the autoimmune skin blistering disease bullous pemphigoid.

268 mune blistering skin diseases, pemphigus and bullous pemphigoid.

269 s in a mouse model of the autoimmune disease bullous pemphigoid.

270 in NC16A are involved in the pathogenesis of bullous pemphigoid.

271 he development of the autoimmune response in bullous pemphigoid.

272 ermal blistering disease that closely mimics bullous pemphigoid.

273 associated with the blistering skin disease, bullous pemphigoid.

274 e relevant in the diagnosis and treatment of bullous pemphigoid.

275 pemphigoid and help distinguishing them from bullous pemphigoid.

276 sh nomacopan as a new therapeutic option for bullous pemphigoid.

277 dase-IV inhibitor-associated noninflammatory bullous pemphigoid.

278 as valuable medications in the treatment of bullous pemphigoid.

279 nd for the clinical benefit of patients with bullous pemphigoid.

280 vulgaris were diagnosed; there was 1 case of bullous pemphigoid; and 1 suspected case of paraneoplast

281 form of the disease, characterized by large bullous peripheral schisis involving the posterior pole,

282 eveloped moderate to severe tractional RD or bullous RD in the control group by day 10 compared with

283 ilated fundus examination showed an inferior bullous RD with no evidence of retinal breaks, while a l

284 eral nonperfusion occurred only in eyes with bullous retinal detachment (38% of cases).

285 Bullous retinal detachment is a rare manifestation of ch

286 s who sought treatment from the authors with bullous retinal detachment resulting from CSC between Ja

287 A73-year-old man presented with a bullous retinal detachment without ciliochoroidal detach

288 Consecutive cases of chronic CSC without bullous retinal detachment, seen during the same period,

289 ndus examination was characterized by severe bullous retinal schisis with pre-retinal and intraretina

290 ischemia was associated with the severity of bullous schisis or RD, other vascular anomalies were obs

291 Bullous serous retinal detachment (RD) with retinal pigm

292 e psoriasis (5648), mild psoriasis (85 232), bullous skin diseases (4284), ulcerative colitis (12 203

293 phigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), and Pemph

294 and the recently described ABSIS (autoimmune bullous skin disorder intensity score) instrument.

295 gus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores hav

296 ested serum from patients with EBA (n = 24), bullous systemic lupus erythematosus (BSLE) (n = 3), bul

297 bodies are often detectable in patients with bullous systemic lupus erythematosus (BSLE).

298 , we tested sera from EBA patients (n = 32), bullous systemic lupus erythematosus patients (n = 3), b

299 Twenty-six of 32 EBA sera and two of three bullous systemic lupus erythematosus sera reacted with t

300 A correct diagnosis of bullous variant of chronic CSC with RPE tear is critical